Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Acquisition of BioSpin Clears Antitrust Period; Shareholders' Meeting Scheduled

NEW YORK (GenomeWeb News) – Bruker BioSciences said today that the Hart-Scott-Rodino waiting period for its proposed acquisition of affiliate Bruker BioSpin has expired.
 
Bruker BioSciences announced in early December that it had launched a $914 million takeover of Bruker BioSpin, which is 100 percent owned by members of the Laukien family, who also own 52 percent of publicly traded Bruker BioSciences.
 
Bruker also said today that it has scheduled a special meeting of its stockholders on Feb. 25 to vote on the proposed acquisition. Shareholders of record as of the close of business on Jan. 11 are eligible to vote on the transaction.
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.